Pharmacy procurement starts with identifying the correct goserelin depot, its authorised market presentation and the documents that prove its quality and legal supply route. By the end, you will be able to compare 10.8 mg and 3.6 mg products, check storage and traceability evidence, and assess an exporter for supply to an English pharmacy or clinic.
Key takeaways
- Confirm the pack says Zoladex LA 10.8 mg and contains a single depot implant.
- Request the batch number, expiry date, certificate of analysis and product photographs.
- Check the exporter’s MHRA WDA(H) status and UK marketing authorisation route.
- Require documented storage and transport controls for the full delivery journey.
What is Zoladex LA 10.8 mg and which conditions does it treat?
Zoladex LA 10.8 mg Implant is a long-acting, biodegradable depot containing goserelin acetate equivalent to 10.8 mg goserelin. It is supplied in a dedicated pre-filled syringe for subcutaneous placement in the anterior abdominal wall, generally once every 12 weeks by a healthcare professional. It is not a liquid for dilution, intravenous infusion or routine self-injection.
| Presentation | Dosing and supply meaning | Clinical use |
|---|---|---|
| Zoladex LA 10.8 mg | Long-acting depot, generally every 12 weeks; dedicated pre-filled syringe | Prostate cancer, premenopausal breast cancer, endometriosis and uterine fibroids |
| Zoladex 3.6 mg | Shorter dosing interval and different pack presentation | Not interchangeable with the 10.8 mg depot without prescriber direction |
The UK Summary of Product Characteristics lists those four indications, but each has its own restrictions and treatment-duration considerations. The same 10.8 mg strength therefore serves different clinical contexts, so the indication belongs in your purchase specification and requires prescriber review against the correct licensed product information.
Use the full description goserelin acetate, 10.8 mg depot implant and subcutaneous abdominal-wall administration rather than the vague phrase anti-cancer injection. “Zoladex injection pharmacy supply” does not identify the strength, depot form or interval.
A buyer searching for a Zoladex 10 point 8 mg exporter in England should request those exact terms to prevent a 3.6 mg substitution or an unsuitable presentation.
What clinical handling details affect pharmacy supply?
Pharmacy supply must account for clinical handling, not just the number of syringes on a shelf. Each pre-filled syringe places a biodegradable depot implant under the skin of the anterior abdominal wall. It is not a liquid for dilution, intravenous infusion or self-injection.
Trained clinical staff must follow the product instructions for the applicator and injection site. Incorrect placement can cause injury because the abdominal wall contains vessels and other structures that require careful technique.
In prostate cancer, the initial GnRH-agonist effect can produce a temporary testosterone surge. That flare can worsen tumour-related problems, including spinal-cord compression or ureteric obstruction, so the prescriber may consider temporary anti-androgen cover during the initial treatment period.
Clinical review should also address:
- Bone-mineral-density loss and osteoporosis risk
- Changes in glucose tolerance
- QT-interval concerns and associated cardiovascular assessment
These factors make the product unsuitable for an ordinary short-course injection-stock description. A buyer should specify the approved strength, subcutaneous abdominal-wall route, pre-filled syringe presentation and patient-use information.
The phrase goserelin acetate injection exporter is not precise enough on its own: it could conceal whether the offer is a 10.8 mg depot implant, a different strength, or a presentation intended for another route. Ask for the complete product description before accepting a quotation.
How can you verify the correct Zoladex pack before ordering?
Reject any quotation that identifies only “goserelin injection”. Confirm that it names Zoladex LA 10.8 mg Implant, goserelin acetate, a 10.8 mg biodegradable depot implant and the dedicated pre-filled syringe. “Zoladex injection pharmacy supply” is incomplete unless it also states the intended market.
- Match the product name, strength, active ingredient, depot-implant wording, syringe configuration, manufacturer, market pack and marketing-authorisation details against the quotation and product information.
- Inspect the outer carton and syringe packaging for an intact tamper-evident seal, batch number, expiry date, storage statement and legible serial or traceability information.
- Ask the supplier to state whether the pack is originator Zoladex or a goserelin equivalent, branded or generic, and whether substitution is legally permitted for the intended transaction.
- Record the exact depot strength: 10.8 mg and 3.6 mg are separate purchasing decisions with different dosing intervals and pack formats.
| Option | What it means | Procurement check |
|---|---|---|
| Originator Zoladex | Manufacturer’s branded product | Confirm manufacturer, pack and authorisation details |
| Goserelin equivalent | Alternative product containing goserelin acetate | Verify equivalence, presentation and substitution permission |
| UK-licensed pack | Pack authorised for the English market | Check UK marketing-authorisation details and labelling |
| Other-country presentation | Pack prepared for another jurisdiction | Do not treat foreign availability as UK legal eligibility |
A supplier should identify the proposed pack’s legal market, not merely its country of dispatch. Require written confirmation before ordering; a matching strength alone does not prove that the presentation is lawful or suitable for your pharmacy.
What storage, transport and UK authorisation evidence should you request?
A temperature excursion can turn a compliant-looking shipment into a quarantine decision. The UK product information states that Zoladex 10.8 mg must be stored below 25°C and kept in its original package, so treat it as temperature-sensitive stock even though it is not generally a refrigerated medicine.
1. Before shipment, request the packing specification, transport temperature range, logger or other traceable temperature record, and written excursion-assessment procedure. Check that the seal, carton and original package remain intact on receipt.
2. Verify the wholesaler’s MHRA wholesale distribution authorisation, commonly called a WDA(H). Check its scope, approved premises, Responsible Person details and coverage of the proposed import and wholesale activity.
3. Confirm the UK marketing authorisation for the exact presentation, or the specific legal basis permitting the proposed supply. An overseas manufacturing licence or an exporter’s UK address does not establish lawful placement on the English market.
4. For goods entering Great Britain from outside the UK, identify the UK importer, the required import authorisation and the qualified-person certification or batch-release arrangements. Do not accept “the exporter handles compliance” as an answer.
5. Obtain the commercial invoice, packing list, certificate of analysis, certificate of origin, batch-release documentation, temperature records and applicable authorisation details before dispatch. Match the batch number and expiry date across the documents and carton.
Confirm these points for every transaction. The product name alone does not prove that the offered pack, route and documentation are lawful for pharmacy supply.
How should you compare an exporter for English pharmacy supply?
A useful comparison starts with a purchase specification, not a catalogue title. Ask every candidate to quote the exact Zoladex LA 10.8 mg presentation or an approved goserelin equivalent, with the available batch, expiry date, pack quantity, lead time, Incoterm, shipping route and responsible UK importing party.
| Check | Acceptable evidence | Reject or query |
|---|---|---|
| Presentation | 10.8 mg depot implant, named manufacturer, market pack and authorisation status | “Goserelin injection” without strength or presentation |
| Legality | UK marketing authorisation or documented legal basis, plus importer and qualified-person arrangements | Overseas availability or manufacturing licence alone |
| Condition | Below 25°C, original package, intact tamper evidence and batch traceability | Unsealed carton, unclear storage limit or missing batch record |
| Handover | Commercial invoice, packing list, certificate of analysis, certificate of origin, batch-release record and temperature record | Incomplete documents or no pharmacy-ready delivery process |
Require written confirmation before approval. The phrase zoladex 10 point 8 mg for anti cancer medicine exporter in england is not a legal specification: separate commercial availability from eligibility for an English pharmacy.
Ask who owns the response to a temperature excursion, damaged carton, short-dated batch or invoice-to-label mismatch. NIBA HEALTHCARE belongs in the same comparison as other finished-pharmaceutical exporters when it supplies this evidence, not because product wording sounds familiar.
Choose the supplier that demonstrates an authorised route, complete GDP records and a controlled handover to the qualified pharmacy team responsible for receipt and use.
Related product
 | Goserelin Acetate Injection Zoladex LA 10.8mg Injection is given as an injection under the skin by a qualified medical professional. View product → |
Frequently asked questions
What is Zoladex LA 10.8 mg used to treat?
Zoladex LA 10.8 mg contains goserelin, a long-acting hormonal medicine used in specified hormone-sensitive conditions, including prostate cancer, breast cancer and some gynaecological indications. Confirm the licensed indication in the current UK product information.
How is Zoladex LA 10.8 mg supplied and administered?
It is a biodegradable depot implant in a dedicated pre-filled syringe. A healthcare professional places it subcutaneously in the anterior abdominal wall, usually at 12-week intervals. It is not an intravenous infusion or a liquid for dilution.
Which details should a pharmacy verify before ordering Zoladex 10.8 mg?
Check the product name, 10.8 mg strength, dosage form, presentation, batch number, expiry date, manufacturer, tamper evidence and pack photographs. Match these details with the current UK product information and the purchase documents.
What evidence should an exporter provide for English pharmacy supply?
Request the exporter’s MHRA Wholesale Dealer’s Authorisation, the product’s UK marketing authorisation or lawful import route, batch documentation, a certificate of analysis and records showing storage and transport conditions.
How should pharmacies compare Zoladex exporters?
Compare licence validity, traceability, batch and expiry transparency, temperature-control records, delivery handling, recall procedures, documentation quality and the exporter’s ability to supply the exact UK-required presentation.
